On Nov. 18, they became the first in the world to release full late-stage trial data. Britain's AstraZeneca is seeking approval for its vaccine in Britain after announcing interim late-stage trial data on Nov. 23. However, it is not clear how the regulator will deal with the different dosages in the efficacy data in its assessment. US firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. Russia said on Nov. 24 its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results.

Source: Mint December 27, 2020 12:11 UTC